Rinvoq ER 30 MG tablet UU 30S
Ended Awarded Last action
- Contract number
- SPE2DR26FXUY3
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $11,383
Award facts
- Contract value 100% obligated
- $11,382.77 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $11,382.77 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count unit dose packages) on January 22, 2026, with a completion date of January 23, 2026. The award is non-set-aside and structured as a firm fixed-price delivery order. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor, with its parent company Cencora, Inc. (doing business as AmerisourceBergen) providing corporate oversight. The place of performance is located in Conshohocken, PA.
This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. The IDC enables AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, and vaccines to support the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems worldwide. RINVOQ (upadacitinib) is a Janus kinase inhibitor used in the treatment of rheumatoid arthritis and other inflammatory conditions, representing the type of specialty pharmaceutical product routinely procured through this vehicle to support military medical readiness and veteran healthcare needs.
Quick answers
Who was awarded contract SPE2DR26FXUY3?
SPE2DR26FXUY3 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 22, 2026.
How much is contract SPE2DR26FXUY3 worth?
The government has obligated $11,383 on SPE2DR26FXUY3.
Is contract SPE2DR26FXUY3 an order under another contract?
Yes. SPE2DR26FXUY3 is a delivery order under SPE2DR25D3004, an indefinite delivery contract.
Was contract SPE2DR26FXUY3 competed?
The extent of competition for SPE2DR26FXUY3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award